Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Flex Pharma Inc    FLKS

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/14/2017 08/15/2017 08/16/2017 08/17/2017 08/18/2017 Date
3.3(c) 3.43(c) 3.5(c) 3.6(c) 3.48 Last
30 274 36 857 16 232 25 623 66 558 Volume
+2.48% +3.94% +2.04% +2.86% -3.33% Change
More quotes
Financials ($)
Sales 2017 1,84 M
EBIT 2017 -42,0 M
Net income 2017 -42,0 M
Debt 2017 -
Yield 2017 -
Sales 2018 6,18 M
EBIT 2018 -54,0 M
Net income 2018 -53,2 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 35,2x
Capi. / Sales2018 10,5x
Capitalization 64,7 M
More Financials
Company
Flex Pharma, Inc. operates as a biotechnology company.It engages in developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions.The company operates through two segments: Consumer Operations and Drug Development.The... 
More about the company
Surperformance© ratings of Flex Pharma Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FLEX PHARMA INC
08/03 FLEX PHARMA : to Report Second Quarter 2017 Results on August 2, 2017
08/03 FLEX PHARMA : Initiates ALS Phase 2 Trial with FLX 787 in US
08/03 FLEX PHARMA : Names William McVicar President and Chief Executive Officer
08/02 FLEX PHARMA,INC. (NASDAQ : FLKS) Files An 8-K Results of Operations and Financia..
08/02 FLEX PHARMA : reports 2Q loss
08/02 FLEX PHARMA : Reports Second Quarter 2017 Financial Results
08/02 FLEX PHARMA INC : Investor Network: Flex Pharma, Inc. to Host Earnings Call
08/01 FLEX PHARMA : Initiates ALS Phase 2 Trial with FLX-787 in US
07/31 FLEX PHARMA : Names William McVicar President and Chief Executive Officer
07/27 FLEX PHARMA : Corporate News Blog - FDA Grants Fast Track Designation to Flex Ph..
More news
Sector news : Bio Therapeutic Drugs
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Bio Therapeutic Drugs
Latest Tweets
08/08Flex Pharma upgraded by Zacks Investment Research to hold.  
08/07Jefferies Group LLC Lowers Flex Pharma FY2017 Earnings Estimates to ($2.20) P.. 
08/05Flex Pharma 2017 Q2 - Results - Earnings Call Slides  
08/05Want automatic email alerts for $KHC $BZUN $FLKS $VIAS $SURG? Subscribe to Ma.. 
08/02Flex Pharma Reports Second Quarter 2017 Financial Results  
More tweets
Qtime:33
News from SeekingAlpha
08/05 Flex Pharma 2017 Q2 - Results - Earnings Call Slides
08/05 Flex Pharma's (FLKS) CEO Bill McVicar on Q2 2017 Results - Earnings Call Tran..
08/02 Flex Pharma beats by $0.07, misses on revenue
08/01 Flex Pharma launches mid-stage study of FLX-787 in ALS
07/31 New chief at Flex Pharma
Chart FLEX PHARMA INC
Duration : Period :
Flex Pharma Inc Technical Analysis Chart | FLKS | US33938A1051 | 4-Traders
Technical analysis trends FLEX PHARMA INC
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 21,0 $
Spread / Average Target 483%
EPS Revisions
Managers
NameTitle
William K. McVicar President & Chief Executive Officer
Christoph H. Westphal Chairman
John McCabe Chief Financial Officer & Treasurer
Thomas C. Wessel Chief Medical Officer
Peter Barton Hutt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
FLEX PHARMA INC-31.82%65
AMGEN14.77%122 447
CELGENE CORPORATION10.22%99 812
GILEAD SCIENCES1.02%94 471
REGENERON PHARMACEUTICALS27.64%49 721
VERTEX PHARMACEUTICALS101.63%37 450